ZENATSEHAY GEBRETSADIK: Open Payments
NPI 1053087106 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,263 in 196 payments from 18 companies in 2025. Trend: 2023 $3,580 · 2024 $3,113 · 2025 $4,263
Food & beverage: $4,151Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $476 |
| Lundbeck LLC | 22 | $413 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $411 |
| ABBVIE INC. | 19 | $402 |
| Vanda Pharmaceuticals Inc. | 13 | $343 |
| Alkermes, Inc. | 20 | $340 |
| Axsome Therapeutics, Inc. | 15 | $324 |
| Neurocrine BioSciences, Inc. | 11 | $311 |
| Janssen Pharmaceuticals, Inc | 10 | $284 |
| Neos Therapeutics, LP | 8 | $174 |
Products named: CAPLYTA, VRAYLAR, FANAPT, ARISTADA, INGREZZA, Auvelity, REXULTI, AUSTEDO XR.
Industry payments across MD — which companies pay providers there.
